Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Y. | - |
dc.contributor.author | Han, M. | - |
dc.contributor.author | Shin, D. | - |
dc.contributor.author | Song, C. | - |
dc.contributor.author | Hahn, H.-G. | - |
dc.date.available | 2020-02-29T09:44:51Z | - |
dc.date.created | 2020-02-11 | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 0022-2623 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17476 | - |
dc.description.abstract | Novel azetidines based on the 3-aryl-3-oxypropylamine scaffold were designed, synthesized, and evaluated as TRIs. Reduction of 1 followed by Swern oxidation and then Grignard reaction gave 3. The alkylation of 3 provided the corresponding azetidine derivatives 6, of which the two most promising, 6bd and 6be, were selected from 86 prepared analogues based on their biological profiles. Compound 6be showed activity in vivo in FST at 10 mg/kg IV or 20-40 mg/kg PO. © 2012 American Chemical Society. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.relation.isPartOf | Journal of Medicinal Chemistry | - |
dc.title | Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000309153500022 | - |
dc.identifier.doi | 10.1021/jm3008294 | - |
dc.identifier.bibliographicCitation | Journal of Medicinal Chemistry, v.55, no.18, pp.8188 - 8192 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84866840102 | - |
dc.citation.endPage | 8192 | - |
dc.citation.startPage | 8188 | - |
dc.citation.title | Journal of Medicinal Chemistry | - |
dc.citation.volume | 55 | - |
dc.citation.number | 18 | - |
dc.contributor.affiliatedAuthor | Shin, D. | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | antidepressant agent | - |
dc.subject.keywordPlus | azetidine derivative | - |
dc.subject.keywordPlus | fluoxetine | - |
dc.subject.keywordPlus | nisoxetine | - |
dc.subject.keywordPlus | vanoxerine | - |
dc.subject.keywordPlus | alkylation | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | area under the curve | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | drug activity | - |
dc.subject.keywordPlus | drug bioavailability | - |
dc.subject.keywordPlus | drug design | - |
dc.subject.keywordPlus | drug half life | - |
dc.subject.keywordPlus | drug screening | - |
dc.subject.keywordPlus | drug synthesis | - |
dc.subject.keywordPlus | Grignard reaction | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | maximum plasma concentration | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | oxidation kinetics | - |
dc.subject.keywordPlus | substitution reaction | - |
dc.subject.keywordPlus | Swern oxidation | - |
dc.subject.keywordPlus | time to maximum plasma concentration | - |
dc.subject.keywordPlus | Animals | - |
dc.subject.keywordPlus | Antidepressive Agents | - |
dc.subject.keywordPlus | Azetidines | - |
dc.subject.keywordPlus | Behavior, Animal | - |
dc.subject.keywordPlus | Drug Design | - |
dc.subject.keywordPlus | HEK293 Cells | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Inhibitory Concentration 50 | - |
dc.subject.keywordPlus | Mice | - |
dc.subject.keywordPlus | Neurotransmitter Uptake Inhibitors | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.